

2nd October 2023				
	Activity	Speaker	Affiliation	Title
Conference opening				
13:00-14:00	Registration			
14:00-14:15	Conference opening	Authorities, DSM delegates, Marcello Manfredi & Daniela Cecconi		
14:15-14:55	Plenary lecture	Guido Bommer	Université Catholique de Louvain, Belgium	Uncommon post-translational modifications in neurodegenerative and neuromuscular diseases
14:55-15:35	Keynote	Karl Mechtler	Research Institute of Molecular Pathology, Vienna	Is it possible to analyze 6000 proteins with a CV < 10 % from a single cell proteomics standard?
Session 1: MS-omics in aging and neurodegenerative diseases, chairs: Mattia Bellan & Marcello Manfredi				
15:35-15:50		Laura Brunelli	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Assessing Adherence to Healthy Dietary Habits: the plasma nutrimental fingerprints in frail elderly
15:50-16:05		Federica Carrillo	Institute of Genetics and Biophysics, National Research Council, Napoli	Analysis of lipidomic profile in Parkinson's disease patients carrying TMEM175 gene mutation to define new potential diagnostic markers
16:05-16:20		Paolo Redegalli	Shimadzu Italia S.r.l.	Mass spectrometry, a strong weapon against Alzheimer disease. From early diagnosis to disease biomarkers discovery and metabolomic studies
16:20-16:50	Coffee break	Poster session		
Session 2: MS-omics in cancer diseases, chairs: Daniela Cecconi & Marco Gaspari				
16:50-17:05		Marco Falasca	Curtin University, Perth, Australia	Proteome landscape of pancreatic cancer-derived extracellular vesicle reveals diverse oncogenic variance and identifies SLC5A3 as a novel player in pancreatic cancer progression
17:05-17:20		Marco Ghirimoldi	University of Piemonte Orientale	Investigating the Role of Circulating small extracellular vesicles Lipids in Prostate Cancer
17:20-17:35		Gloria Sala	University of Piemonte Orientale	Mucosa-associated microbiota and metabolome signatures discriminate between low-grade and high-grade dysplastic colon polyps
17:35-17:50		Erik Verschuuren	EVOSEP	Pushing the boundaries for Automated End-to-End, high-throughput and standardized single cell proteomics
17:50-18:05		Veronica De Giorgis	University of Piemonte Orientale	Advanced Proteomic and Bioinformatic Approaches Revealed New Potential Therapeutic Targets for Soft Tissue Sarcoma.
18:15-19:30	Welcome party	Poster session		

3rd October 2023				
Session 3: MS in biomarker and drug discovery and precision medicine, chairs: Fulvio Magni & Marcello Manfredi				
9:00-9:40	Keynote (on-line)	Paola Picotti	ETH Zurich	Decoding the protein dance
9:40-9:55		Jessica Brandi	University of Verona	Exploring the epi-proteomic landscape of pancreatic cancer stem cells by super SILAC-based mass spectrometry
9:55-10:10		Cermenati Gaia	SCIEX	Comprehensive characterization of protein therapeutics using electron activated dissociation (EAD).
10:10-10:25		Giuliana Siragusa	University of Verona	Proteomics reveals mitochondrial targeting by a tri-phenyl-phosphonium-substituted fatty acid in pancreatic cancer.
10:25-10:40		Shahzaib Khoso	University of Piemonte Orientale	An integrated novel approach to artificial intelligence-omics strategies for precision medicine
10:40-11:10	Coffee break	Poster session		
Sessione 4: MS-omics in age-related diseases, chairs: Daniela Cecconi & Donatella Caruso				
11:10-11:50	Keynote	Therry Durand	Institut des Biomolécules Max Mousseron, Université de Montpellier, CNRS	Oxidized PUFAs are more promising for health: the case of F4-neuroprostanes and F2-isoprostanes
11:50-12:05		Stefanuto Pierre-Hugues	Liege University, Belgium	Improving analytical and annotation robustness in small molecule metabolomics using GCxGC-HRTOFMS
12:05-12:20		Claudio De Felice	Azienda Ospedaliera Universitaria Senese - Siena	Investigating the effects of pre- and post-biotics on neurotransmitters levels and gut-brain axis in Rett syndrome
12:20-12:35		Elena Ciceri	Thermo Scientific	Thermo Scientific Exactive GC Orbitrap for metabolomics
12:35-12:50		Salvatore Villani	University of Piemonte Orientale	LC-MS/MS targeted metabolomics of Kynurenine Pathway Catabolites: Insights from Selective Indoleamine or Tryptophan 2,3-Dioxygenase Inhibition and IDO1 Inhibitor Potency
12:50-13:00	Conclusions			